• Most Popular
  • Most Shared
A boy cries as he recuperates after surgery during "Operation Smile" at a hospital in Manila's Makati financial district October 26, 2009. Operation Smile aim to provide free surgery for about a hundred children inflicted with cleft lips, cleft palates, and other facial deformities over a period of five days in Makati.  REUTERS/Cheryl Ravelo

Pictures of the year: Health

A look at the year's best health photos.   Slideshow 

    Doctors test double Tamiflu dose to cut H5N1 deaths

    HONG KONG
    Wed Mar 28, 2007 10:34am EDT
    A pharmacy worker conducts research to produce Oseltamivir capsules, a local version of Tamiflu, at the country's Kimia Farma laboratory in Bandung, west Java, February 17, 2006. Doctors in Asia and the United States will give double doses of Tamiflu to patients suffering bird flu and severe seasonal human flu from May in a trial aimed at cutting high death rates from avian flu. REUTERS/Dadang Tri

    HONG KONG (Reuters) - Doctors in Asia and the United States will give double doses of Tamiflu to patients suffering bird flu and severe seasonal human flu from May in a trial aimed at cutting high death rates from avian flu.

    Health

    People infected with the H5N1 bird flu virus are now prescribed the standard dose of Tamiflu, which is one capsule twice daily for five days.

    But less than half the patients survive.

    "In animal studies, higher doses of Tamiflu have resulted in higher cure rates for H5N1. The death rate from H5N1 is 60 percent, we want to see if we can solve this problem," said Tawee Chotpitayasunondh, senior medical officer at Thailand's Ministry of Public Health.

    Indonesia, Thailand, Vietnam and the United States will participate in the Tamiflu clinical trial.

    All bird flu victims will be included in the trial and each country will pick 100 patients suffering from severe human flu.

    In both categories, half of the participants will be given the standard Tamiflu dosage, while the other half will be given double doses, or 150 mg orally, twice daily for 10 days.

    Severe human flu cases would be included because some symptoms and complications were similar to H5N1, such as pneumonia.

    "We'll find out if it is safe to give double dose," Tawee said.

    "We will look at clinical signs such as whether the person is feeling better. We will take secretions from the throat and lungs and check for viral load. We will check to see the progression."

    For the moment, there are no commercially available vaccines against the H5N1 virus and Tamiflu is regarded as the best front-line defense against the disease if given to a patient during the early onset of symptoms. Many nations have stockpiled the drug in the event of a bird flu pandemic.

    News of the trial comes after growing concerns Tamiflu could induce psychiatric symptoms. Japan warned doctors this week not to give Tamiflu to young people, after two teenagers fell from buildings after taking it.

    "We are concerned about the cases in Japan, but Japan consumes a lot of the total production of Tamiflu (for human flu). If you use a lot, you may have more side effects," Tawee said. "But we will closely monitor our subjects."

    While H5N1 threatens mainly birds, experts fear it can trigger a pandemic once it learns to transmit efficiently among people. If it does, millions could die.



    More from Reuters

    Photo

    Senate on track to pass healthcare bill

    WASHINGTON (Reuters) - Senate Democrats moved closer on Monday to passing landmark healthcare legislation by Christmas after scoring a win in the first big test vote and gaining the support of a powerful lobbying group for doctors. | Video

    Photo

    Political risk clouds Asia

    The economic outlook is strong, but the danger of a sudden correction hangs over Asian markets - as political risks could turn sunshine to storm clouds in the blink of an eye.  Full Article 

    Two men shake hands in a file photo.    REUTERS/File

    Let's make a deal

    The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article